Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Smoldering Multiple Myeloma 1Pancreatic Neoplasms 1Acute Graft Versus Host Disease 1

Interventions

Dexamethasone 14Lenalidomide 13Calcium Dobesilate 7carfilzomib 4dexamethasone acetate 3dexamethasone 21-phosphate 3auricularum 3Melphalan 3Leflunomide 3Curcumin 3isatuximab 2iberdomide 2daratumumab 2Denosumab 2Cyclophosphamide 2Bortezomib 2selinexor 1pomalidomide 1poly ICLC 1piperine 1pembrolizumab 1ixazomib 1ibrutinib 1fludarabine phosphate 1fludarabine 1elotuzumab 1citarinostat 1atezolizumab 1Urination 1Transplantation, Autologous 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Smoldering Multiple Myeloma × Cholestyramine Resin × Clear all
NCT05014646 2026-04-30

Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients

City of Hope Medical Center

Phase 2 Active not recruiting
27 enrolled
Plasma cell

Smoldering Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡